Breath of Innovation
Verona Pharma is developing life enhancing treatments for chronic respiratory diseases.
Verona Pharma Announces the US FDA has Accepted the New Drug Application Filing for Ensifentrine for the Maintenance Treatment of COPD
PDUFA Target Action Date of June 26, 2024 Ensifentrine, if approved, is expected to be the first novel mechanism available for the maintenance treatment of COPD in more than a decade
We’re a clinical‑stage biopharmaceutical company focused on developing and commercializing innovative prescription medicines.
We are focused on treating respiratory diseases with significant unmet medical needs, such as COPD, cystic fibrosis and asthma. The Company is listed on the Nasdaq Global Market in the United States under the VRNA ticker.
The unmet need
→COPD
Cystic Fibrosis
Asthma
Chronic Obstructive Pulmonary Disease is a progressive respiratory disease without a cure.
The condition causes loss of lung function, hospitalizations and death. COPD affects approximately 384 million people worldwide. It is the third leading cause of death globally, according to the Global Initiative for Chronic Obstructive Lung Disease.
Find out moreLatest news
Latest Film
Ensifentrine is a first-in-class investigational drug under review by the US FDA for the maintenance treatment of COPD
Verona Pharma
Investor Information
© Verona Pharma plc 2023. All rights reserved
Ensifentrine (RPL554): Mechanism of action
Ensifentrine is a Phase 3, first-in-class candidate for the maintenance treatment of COPD.